NCO 700

Drug Profile

NCO 700

Latest Information Update: 02 Nov 2007

Price : $50

At a glance

  • Originator Nippon Chemiphar
  • Developer Hitachi Chemical; Nippon Chemiphar; Nonindustrial source
  • Class Anti-ischaemics; Antiarrhythmics; Antineoplastics; Piperazines; Small molecules
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Arrhythmias; Cancer; Ischaemic heart disorders

Most Recent Events

  • 19 Feb 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 19 Feb 2001 Preclinical development for Cancer in Japan (Unknown route)
  • 19 Feb 2001 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top